Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases
It has recently been recognized that neurodegenerative diseases are caused by common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Each type of neurodegenerative disease is characterized by the specific protein that aggregates. In these days, the pathw...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2018.00265/full |
id |
doaj-de7377433e9f46d9a33015210ca2b62e |
---|---|
record_format |
Article |
spelling |
doaj-de7377433e9f46d9a33015210ca2b62e2020-11-24T21:20:00ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-04-01910.3389/fneur.2018.00265342547Role of Neuroimaging as a Biomarker for Neurodegenerative DiseasesSoichiro ShimizuDaisuke HiroseHirokuni HatanakaNaoto TakenoshitaYoshitsugu KanekoYusuke OgawaHirofumi SakuraiHaruo HanyuIt has recently been recognized that neurodegenerative diseases are caused by common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Each type of neurodegenerative disease is characterized by the specific protein that aggregates. In these days, the pathway involved in protein aggregation has been elucidated. These are leading to approaches toward disease-modifying therapies. Neurodegenerative diseases are fundamentally diagnosed pathologically. Therefore, autopsy is essential for a definitive diagnosis of a neurodegenerative disease. However, recently, the development of various molecular brain imaging techniques have enabled pathological changes in the brain to be inferred even without autopsy. Some molecular imaging techniques are described as biomarker in diagnostic criteria of neurodegenerative disease. Magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), and amyloid imaging are described in the diagnostic guidelines for Alzheimer’s disease in the National Institute on Aging-Alzheimer’s Association. MRI, dopamine transporter (DAT) imaging, and 123I-metaiodobenzyl-guanidine (MIBG) myocardial scintigraphy listed in the guidelines for consensus clinical diagnostic criteria for dementia with Lewy bodies are described as potential biomarkers. The Movement Disorder Society Progressive Supranuclear Palsy Study Group defined MRI, SPECT/PET, DAT imaging, and tau imaging as biomarkers. Other diagnostic criteria for neurodegenerative disease described neuroimaging findings as only characteristic finding, not as biomarker. In this review, we describe the role of neuroimaging as a potential biomarker for neurodegenerative diseases.http://journal.frontiersin.org/article/10.3389/fneur.2018.00265/fullamyloidbiomarkerDATdementiaMIBGneuroimaging |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Soichiro Shimizu Daisuke Hirose Hirokuni Hatanaka Naoto Takenoshita Yoshitsugu Kaneko Yusuke Ogawa Hirofumi Sakurai Haruo Hanyu |
spellingShingle |
Soichiro Shimizu Daisuke Hirose Hirokuni Hatanaka Naoto Takenoshita Yoshitsugu Kaneko Yusuke Ogawa Hirofumi Sakurai Haruo Hanyu Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases Frontiers in Neurology amyloid biomarker DAT dementia MIBG neuroimaging |
author_facet |
Soichiro Shimizu Daisuke Hirose Hirokuni Hatanaka Naoto Takenoshita Yoshitsugu Kaneko Yusuke Ogawa Hirofumi Sakurai Haruo Hanyu |
author_sort |
Soichiro Shimizu |
title |
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases |
title_short |
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases |
title_full |
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases |
title_fullStr |
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases |
title_full_unstemmed |
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases |
title_sort |
role of neuroimaging as a biomarker for neurodegenerative diseases |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2018-04-01 |
description |
It has recently been recognized that neurodegenerative diseases are caused by common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Each type of neurodegenerative disease is characterized by the specific protein that aggregates. In these days, the pathway involved in protein aggregation has been elucidated. These are leading to approaches toward disease-modifying therapies. Neurodegenerative diseases are fundamentally diagnosed pathologically. Therefore, autopsy is essential for a definitive diagnosis of a neurodegenerative disease. However, recently, the development of various molecular brain imaging techniques have enabled pathological changes in the brain to be inferred even without autopsy. Some molecular imaging techniques are described as biomarker in diagnostic criteria of neurodegenerative disease. Magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), and amyloid imaging are described in the diagnostic guidelines for Alzheimer’s disease in the National Institute on Aging-Alzheimer’s Association. MRI, dopamine transporter (DAT) imaging, and 123I-metaiodobenzyl-guanidine (MIBG) myocardial scintigraphy listed in the guidelines for consensus clinical diagnostic criteria for dementia with Lewy bodies are described as potential biomarkers. The Movement Disorder Society Progressive Supranuclear Palsy Study Group defined MRI, SPECT/PET, DAT imaging, and tau imaging as biomarkers. Other diagnostic criteria for neurodegenerative disease described neuroimaging findings as only characteristic finding, not as biomarker. In this review, we describe the role of neuroimaging as a potential biomarker for neurodegenerative diseases. |
topic |
amyloid biomarker DAT dementia MIBG neuroimaging |
url |
http://journal.frontiersin.org/article/10.3389/fneur.2018.00265/full |
work_keys_str_mv |
AT soichiroshimizu roleofneuroimagingasabiomarkerforneurodegenerativediseases AT daisukehirose roleofneuroimagingasabiomarkerforneurodegenerativediseases AT hirokunihatanaka roleofneuroimagingasabiomarkerforneurodegenerativediseases AT naototakenoshita roleofneuroimagingasabiomarkerforneurodegenerativediseases AT yoshitsugukaneko roleofneuroimagingasabiomarkerforneurodegenerativediseases AT yusukeogawa roleofneuroimagingasabiomarkerforneurodegenerativediseases AT hirofumisakurai roleofneuroimagingasabiomarkerforneurodegenerativediseases AT haruohanyu roleofneuroimagingasabiomarkerforneurodegenerativediseases |
_version_ |
1726004392961769472 |